{"product_id":"harvard-dementia-a-comprehensive","title":"Harvard Dementia A Comprehensive Update 2023","description":"\u003ch3\u003eHarvard Dementia A Comprehensive Update 2023\u003c\/h3\u003e\u003cbr\u003eHarvard Dementia A Comprehensive Update 2023  The spectrum of neurodegenerative diseases spans from asymptomatic preclinical disease to very mild cognitive impairment to frank dementia. Alzheimer’s disease (AD), the most common cause of dementia, is a devastating condition that affects patients and their whole family of caregivers at tremendous emotional and financial cost.\u003cbr\u003e\u003ch4\u003e\u003cspan style=\"color: #1b1919; font-size: 22px;\"\u003eFormat : 39 Videos + Syllabus\u003c\/span\u003e\u003c\/h4\u003e\n\u003cdiv class=\"prod-filesize\"\u003e\n\u003ch3\u003eFile Size : 9.6 GB\u003c\/h3\u003e\n\u003c\/div\u003e\u003cbr\u003e \u003cbr\u003e\u003cul\u003e\n\u003cli\u003eThe spectrum of neurodegenerative diseases spans from asymptomatic preclinical disease to very mild cognitive impairment to frank dementia. Alzheimer’s disease (AD), the most common cause of dementia, is a devastating condition that affects patients and their whole family of caregivers at tremendous emotional and financial cost.\u003c\/li\u003e\n\u003cli\u003eDementia: A Comprehensive Update is a three-and-a-half day, annual, review course designed by clinicians for clinicians. The course is organized by Neurology faculty members of Harvard Medical School who specialize in the care of patients with cognitive and behavioral disorders at Brigham and Women’s Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, McLean Hospital and Banner Sun Health Research Institute\/Banner Health. The course takes a practical and multidisciplinary approach to understanding and treating dementia and is designed for healthcare professionals involved in the diagnosis, management and investigation of disease states causing dementia. This cutting-edge course is in its 26th year, includes locally, nationally and internationally renowned faculty and attracts 300-400 participants from throughout the U.S. and the world.\u003c\/li\u003e\n\u003cli\u003eThe organization of the course takes an integrative approach by interweaving lectures within the main program that establish the neuroanatomical and cognitive framework underlying disorders of cognition; address specific diseases (e.g. AD, vascular cognitive impairment\/dementia, Parkinsonian dementias, frontotemporal dementias); and discuss the latest clinical practices and research approaches to the diagnosis and treatment of dementing illnesses (e.g. Alzheimer’s Association Clinical Practice Guidelines; practical office-based assessments; application of biomarkers, spinal fluid and amyloid\/tau PET imaging in dementia; clinical treatment; prevention and experimental trials), with optional, fee-based programs. Lectures and programs also provide education on special topics in dementia such as managing problem behaviors; disclosure of diagnosis and risk; chronic traumatic encephalopathy; caregiving in dementia; pain, palliation, hospice care; medicolegal issues; capacity and competence; undue influence; driving; long-term\/ nursing home care; delirium and dementia; neuroethics; advanced care planning; and neuropsychology of aging.\u003c\/li\u003e\n\u003cli\u003e\n\u003ch2\u003eWho Should Attend\u003c\/h2\u003e\n\u003c\/li\u003e\n\u003cli style=\"list-style-type: none;\"\u003e\n\u003cul\u003e\n\u003cli\u003ePrimary Care Physicians\u003c\/li\u003e\n\u003cli\u003eSpecialty Physicians\u003c\/li\u003e\n\u003cli\u003eNurses\u003c\/li\u003e\n\u003cli\u003eNurse Practitioners\u003c\/li\u003e\n\u003cli\u003ePhysician Assistants\u003c\/li\u003e\n\u003cli\u003ePsychologists\u003c\/li\u003e\n\u003cli\u003eSocial Workers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch3\u003eLearning Objectives\u003c\/h3\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003eUpon completion of this activity, participants will be able to:\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli style=\"list-style-type: none;\"\u003e\n\u003cul\u003e\n\u003cli\u003eDescribe current understanding of epidemiology, risk factors, pathobiology, societal costs, clinical differences, gaps in knowledge, and challenges in distinguishing and managing the spectra of normal cognitive aging, mild cognitive impairment (MCI), Alzheimer’s disease (AD) and other neurodegenerative dementias\u003c\/li\u003e\n\u003cli\u003eDistinguish pre-clinical AD, MCI due to AD\/prodromal AD and AD dementia phases\u003c\/li\u003e\n\u003cli\u003eSummarize tiered diagnostic and management approaches, and future experimental therapeutics strategies under consideration for risk reduction, prevention diagnosis and treatment of the AD spectrum\u003c\/li\u003e\n\u003cli\u003eDifferentiate, based on neuropathology, affected neural systems, clinical criteria and biomarkers, AD and its atypical variants from other common dementias including Dementia with Lewy Bodies (DLB), Vascular Cognitive Impairment (VCI)\/Vascular-Ischemic Dementia, Frontotemporal Degeneration (FTD), Parkinson’s disease with Dementia (PDD), Parkinson’s-Plus Syndromes and less common dementias\u003c\/li\u003e\n\u003cli\u003eIdentify and explain the importance of evidence-based and coordinated individualized approaches to the evaluation and management of MCI, AD and neurodegenerative dementias that stress combining: (i) early and accurate detection, assessment and monitoring; (ii) psycho-education and non-pharmacological interventions; (iii) pharmacological strategies; and (iv) caregiver, psychosocial\/environmental, quality of life, ethical, medico-legal and end-of-life considerations\u003c\/li\u003e\n\u003cli\u003eApply data-supported diagnostic, behavioral, pharmacological, and environmental strategies, including appropriate and tiered use of cognitive tests\/measures, labs, and imaging studies\/biomarkers; and delineation of expectations, roles (i.e., indications and benefits), cautions (i.e., risks, side-effects, warnings) and treatment nuances in the interdisciplinary management of CI, AD and neurodegenerative dementias\u003c\/li\u003e\n\u003cli\u003eDemonstrate neural processes and functional networks that support perception and cognitive systems including memory, language, attentional, frontal\/executive, visuospatial and motor systems\u003c\/li\u003e\n\u003cli\u003eExplain the roles of office-based screening instruments, mental status exam (MSE) and neuropsychological evaluation in the diagnosis and management of dementia; develop efficient approaches to MSE and use of screening instruments (e.g. MoCA); and interpret and compare cognitive testing\/neuropsychological performance patterns for different conditions and clinical syndromes (e.g. MCI, AD, FTD, primary progressive aphasias, posterior cortical atrophy, DLB)\u003c\/li\u003e\n\u003cli\u003eUtilize appropriate laboratory tests, imaging studies, and neuropsychological testing for the diagnosis of dementia in clinical practice; incorporate appropriate use of clinical biomarkers (e.g. CSF a-beta\/tau, MRI, FDG- and Amyloid-PET) in evaluation of neurodegenerative dementias to differentiate AD and non-AD processes; and explain clinical versus research use and apply appropriate use criteria\/guidelines to the clinical use of amyloid PET imaging in the diagnosis of AD-like syndromes\u003c\/li\u003e\n\u003cli\u003eApply data-supported pharmacologic management strategies including the roles (i.e., indications and benefits), cautions (i.e., risks, side-effects, warnings) and potential alternatives to using cholinesterase inhibitors, memantine, antipsychotics and antidepressants in dementia and AD\u003c\/li\u003e\n\u003cli\u003eIntegrate a holistic approach to management of problem behaviors and neuropsychiatric symptoms (e.g. aggression, apathy, anxiety, depression, psychosis) in individuals with dementia that stresses education and behavioral and non-pharmacological interventions as first-line approaches\u003c\/li\u003e\n\u003cli\u003eDiscuss the important role, and the challenges and risks caregivers face; describe strategies to help dementia caregivers cope and better care for themselves and for patients with dementia including psychosocial counseling, community support resources and respite care\u003cbr\u003eIdentify delirium\/encephalopathy and Chronic Traumatic Encephalopathy (CTE) as a dementia risks or entities\u003c\/li\u003e\n\u003cli\u003eDevelop appropriate practices concerning medico-legal and safety issues surrounding patients with dementia, including capacity with regards to medical care, finances, contracts, independent living and driving; and integrate medico-legal and safety practices to support and safeguard patients and families, and the public-at-large\u003c\/li\u003e\n\u003cli\u003eDescribe issues related to dementia neuroethics, and implement effective practices in the long-term care\/nursing-home environment and in end-stage dementia regarding medical, legal and ethical issues including recognition and treatment of delirium\/encephalopathy and pain, providing palliation and hospice care and managing end-of-life issues related to dementia\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eProgram\u003c\/h3\u003e\n\u003ch4 style=\"text-align: center;\"\u003eWednesday, May 31, 2023\u003c\/h4\u003e\n\u003ch4 style=\"text-align: center;\"\u003eDAY ONE\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eIntroduction to the Course\u003cbr\u003eAlireza Atri, MD, PhD\u003cbr\u003eBrad Dickerson, MD, MMSc\u003cbr\u003eLynn Shaughnessy, PsyD, ABPP\/CN\u003c\/li\u003e\n\u003cli\u003eHuman Cognition: An Overview\u003cbr\u003eBrad Dickerson, MD, MMSc\u003c\/li\u003e\n\u003cli\u003eMemory Systems \u0026amp; Amnesia\u003cbr\u003eAndrew Budson, MD\u003c\/li\u003e\n\u003cli\u003eNeuropathology of AD\/ADRD: A Guide for Practicing Clinicians\u003cbr\u003eMatthew P. Frosch, MD, PhD\u003c\/li\u003e\n\u003cli\u003eFrom Proteinopathies to Neuroimaging \u0026amp; Biomarkers in AD\/ADRD: Primer on Practice and Advances\u003cbr\u003eDavid Wolk, MD\u003c\/li\u003e\n\u003cli\u003eAlzheimer's Disease \u0026amp; Related Dementias: Global Perspectives and Opportunities\u003cbr\u003eMaria Carrillo, MD\u003c\/li\u003e\n\u003cli\u003eAlzheimer's Disease Pathobiological Definitions \u0026amp; Prevention Strategies\u003cbr\u003eRandall Bateman, MD\u003c\/li\u003e\n\u003cli\u003ePanel Discussion and Q\u0026amp;A\u003cbr\u003eCourse Directors and Faculty\u003c\/li\u003e\n\u003cli\u003eAfternoon Introductions\u003cbr\u003eAlireza Atri, MD, PhD\u003c\/li\u003e\n\u003cli\u003eAD Dementia: Practical Evaluation \u0026amp; Management in Clinical Practice\u003cbr\u003eAlireza Atri, MD, PhD\u003c\/li\u003e\n\u003cli\u003eMild Cognitive Impairment: Prodromal AD and Beyond\u003cbr\u003eRonald Petersen, MD, PhD\u003c\/li\u003e\n\u003cli\u003eAdvances in AD Experimental Therapeutics\u003cbr\u003eAlireza Atri, MD, PhD\u003c\/li\u003e\n\u003cli\u003ePanel Discussion and Q\u0026amp;A\u003cbr\u003eCourse Directors and Faculty\u003c\/li\u003e\n\u003cli\u003eCocktail Reception with Course Faculty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"text-align: center;\"\u003eThursday, June 1, 2023\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eAttentional and Executive Systems - Don't Leave Home without Them\u003cbr\u003eKirk Daffner, MD, FAAN\u003c\/li\u003e\n\u003cli\u003eNeuropsychology of Aging\u003cbr\u003eSandra Weintraub, PhD, ABPP\/CN\u003c\/li\u003e\n\u003cli\u003eFrontotemporal Dementias: Focus on Behavioral\/Executive Variants\u003cbr\u003eBruce Miller, MD\u003c\/li\u003e\n\u003cli\u003eLanguage Systems \u0026amp; Aphasia-predominant Dementia Syndromes\u003cbr\u003eM. Marsel Mesulam, MD\u003c\/li\u003e\n\u003cli\u003eUpdates on Vascular Cognitive Impairment \u0026amp; Dementia\u003cbr\u003eCharles DeCarli, MD, FAAN, FAHA\u003c\/li\u003e\n\u003cli\u003ePanel Discussion and Q\u0026amp;A\u003cbr\u003eCourse Directors and Faculty\u003c\/li\u003e\n\u003cli\u003eAfternoon Introductions\u003cbr\u003eAlireza Atri, MD, PhD\u003c\/li\u003e\n\u003cli\u003eLewy Body Disease, and Parkinsonian \u0026amp; Sensorimotor-predominant Dementias\u003cbr\u003eJames Galvin, MD, MPH\u003c\/li\u003e\n\u003cli\u003eAssessment of Cognition in Clinical Practice\u003cbr\u003eAlireza Atri, MD, PhD\u003c\/li\u003e\n\u003cli\u003ePractical Compensatory Strategies for Cognitive Decline\u003cbr\u003eLynn Shaughnessy, PsyD, ABPP\/CN\u003c\/li\u003e\n\u003cli\u003eAssessment of Daily Function and Neuropsychiatric Symptoms\/Behavior and Staging of Dementia in Practice\u003cbr\u003eBrad Dickerson, MD, MMSc\u003c\/li\u003e\n\u003cli\u003eTelehealth neuropsychological evaluations for patients with possible neurocognitive disorders: Lessons from COVID\u003cbr\u003eJanet Sherman, PhD\u003c\/li\u003e\n\u003cli\u003eCased-based Assessment and Application of Biomarkers in Dementia Clinical Practice\u003cbr\u003eAlireza Atri, MD, PhD\u003cbr\u003eBrad Dickerson, MD, MMSc\u003cbr\u003eJanet C. Sherman, PhD\u003cbr\u003eDavid Wolk, MD\u003c\/li\u003e\n\u003cli\u003ePanel Discussion and Q\u0026amp;A\u003cbr\u003eCourse Directors and Faculty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 style=\"text-align: center;\"\u003eFriday, June 2, 2023\u003c\/h4\u003e\n\u003ch4 style=\"text-align: center;\"\u003eDAY THREE\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eMorning Introductions\u003cbr\u003eAlireza Atri, MD, PhD\u003c\/li\u003e\n\u003cli\u003eNon-Pharmacological Approaches to Neuropsychiatric Symptoms and Problem Behaviors in Dementia\u003cbr\u003eHelen Kales, MD\u003c\/li\u003e\n\u003cli\u003ePharmacological Management of Behavioral Problems in Dementia\u003cbr\u003eClive Ballard, MDB ChB, MRC Psych, MD\u003c\/li\u003e\n\u003cli\u003ePractical \u0026amp; Ethical Considerations for Disclosure of Dementia-Related Diagnosis and Risk\u003cbr\u003eJason Karlawish, MD\u003c\/li\u003e\n\u003cli\u003eCaregiving in Dementia: Impact, Consequences \u0026amp; Opportunities\u003cbr\u003eMary Mittelman, DrPH\u003c\/li\u003e\n\u003cli\u003ePanel Discussion and Q\u0026amp;A\u003cbr\u003eCourse Directors and Faculty\u003c\/li\u003e\n\u003cli\u003eAfternoon Introductions\u003cbr\u003eBrad Dickerson, MD, MMSc\u003c\/li\u003e\n\u003cli\u003eCommunity Advocacy and Activism For Dementias\u003cbr\u003eKatie Brandt, MM\u003c\/li\u003e\n\u003cli\u003eChronic Traumatic Encephalopathy (CTE) \u0026amp; Dementia\u003cbr\u003eRobert Stern, PhD\u003c\/li\u003e\n\u003cli\u003eDelirium, Encephalopathies and Uncommon Dementias\u003cbr\u003eJeremy Schmahmann, MD\u003c\/li\u003e\n\u003cli\u003ePanel Discussion, Q\u0026amp;A and Conclusions\u003cbr\u003eCourse Directors and Faculty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 style=\"text-align: center;\"\u003eSaturday, June 3, 2023\u003c\/h4\u003e\n\u003ch4 style=\"text-align: center;\"\u003eDAY FOUR\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eIntroduction to Symposium\u003cbr\u003eAlireza Atri, MD, PhD\u003c\/li\u003e\n\u003cli\u003eDementia \u0026amp; The Law: Clinical Pearls on Testamentary Capacity and Undue Influence\u003cbr\u003eJudith G. Edersheim, JD, MD\u003cbr\u003eBruce H. Price, MD\u003c\/li\u003e\n\u003cli\u003ePrinciples \u0026amp; Practice of Mental Capacity and Competence in Dementia: From Finances to Firearms\u003cbr\u003eBarry S. Fogel, MD\u003c\/li\u003e\n\u003cli\u003eDriving, Home \u0026amp; Community Safety and Dementia\u003cbr\u003eMargaret O'Connor, PhD, ABPP\/CN\u003c\/li\u003e\n\u003cli\u003eAdvanced Care Planning \u0026amp; Management of End-stage Dementia, Pain, Palliation \u0026amp; Hospice in Long-Term Care\u003cbr\u003eMary Norman, MD\u003c\/li\u003e\n\u003cli\u003ePanel Discussion, Q\u0026amp;A and Conclusions\u003cbr\u003eCourse Directors and Faculty\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954286825570,"sku":"MED-AMB00287","price":45.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Harvard-Dementia-A-Comprehensive-Update-2023-CME-VIDEOS.jpg?v=1779370040","url":"https:\/\/meducourse.com\/products\/harvard-dementia-a-comprehensive","provider":"Meducourse","version":"1.0","type":"link"}